Home / GU oncology / Prostate / Localized high-risk

Prostate → Localized high-risk

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — local therapy is the foundation; systemic intensification evidence applies to a defined very-high-risk/cN1 population

Who this applies to

Population	Direct-evidence boundary	Not established by the pivotal data
High-risk or locally advanced, nonmetastatic prostate cancer	Confirm clinical stage, PSA, Grade Group, conventional staging, life expectancy, urinary function, and treatment priorities³⁴.	Do not equate a guideline high-risk label with every trial population¹².
STAMPEDE-like high-risk M0 disease	Conventional-imaging M0, WHO performance status 0–2, and cN1 or cN0 with at least two of cT3–4, Gleason 8–10, and PSA ≥40 ng/mL².	The abiraterone result should not be extrapolated to every high-risk patient².

Standard options

Clinical context	Option	Key inclusion	Typical duration
Localized high-risk disease	Radical prostatectomy within planned multimodality care³⁴	Surgical fitness and a plan for pathology-directed postoperative management³⁴.	Procedure plus risk-adapted follow-up³.
Locally advanced or high-risk disease selecting radiation	Definitive radiotherapy plus long-course ADT¹	Localized/locally advanced disease; integrate urinary, bowel, bone, metabolic, and cardiovascular risks¹.	EORTC 22961 compared 6 months with 3 years of androgen suppression¹.
STAMPEDE-like very-high-risk or cN1 M0 disease receiving ADT plus radiotherapy	Add abiraterone plus prednisolone²	Exact STAMPEDE high-risk M0 eligibility required².	ADT 3 years plus abiraterone/prednisolone 2 years in the trial².

Therapy sequencing

Starting point	Treatment order	Evidence boundary
Localized high-risk disease selecting surgery	Radical prostatectomy → pathology- and PSA-directed postoperative surveillance or salvage pathway³⁴.	Do not use the radiotherapy/ADT trials to prescribe postoperative treatment without the surgical pathology and PSA context¹².
Locally advanced or high-risk disease selecting radiation	Definitive radiotherapy plus long-course ADT¹.	EORTC 22961 compares androgen-suppression duration after radiotherapy; it does not select a surgical versus radiation approach¹.
STAMPEDE-like very-high-risk/cN1 M0 disease	ADT plus radiotherapy → add two years of abiraterone/prednisolone while ADT continues for the trial duration².	This sequence requires the exact STAMPEDE-like risk boundary; it is not evidence for every high-risk localized patient².
Biochemical persistence or recurrence after surgery	Move to the early-salvage radiotherapy pathway⁴⁶.	The next decision depends on PSA kinetics, imaging, and pathology rather than routine adjuvant therapy for all⁴⁶.

Surveillance and treatment de-escalation

Setting	PSA	Imaging	Stop/de-escalate	Re-escalate
After radical prostatectomy³⁵	Every 3–6 months for 5 years, then annually³⁵.	Pathology-directed imaging only for symptoms or rising PSA³⁵.	No routine adjuvant radiotherapy for undetectable PSA in the modern-trial population⁴⁶.	Biochemical persistence/recurrence → early salvage radiotherapy pathway⁴⁶.
After definitive radiotherapy plus ADT¹²	Every 6 months¹².	As clinically indicated for symptoms or rising PSA; ADT duration per EORTC 22961 (3 years total androgen suppression after initial 6 months) or protocol STAMPEDE (abiraterone 2 years with 3 years ADT)¹².	Complete planned ADT/abiraterone duration unless toxicity mandates hold; taper or stop ADT only after shared decision at planned end¹².	PSA rise after local therapy → salvage options, systemic intensification, or mHSPC pathway if metastatic³⁵.
STAMPEDE-like intensification²	Per post-RT cadence above; also monitor blood pressure, potassium, and LFTs on abiraterone/prednisolone².	Same as post-RT setting².	Stop abiraterone at 2 years per trial; continue ADT to 3 years².	Metastatic progression → mHSPC page²³.

EAU/NCCN recommend risk-adapted PSA surveillance after local therapy; imaging for symptomatic or high-rate PSA rise³⁵.

Published 6-year MFS 82% vs 69% (ADT+abiraterone vs ADT); not a full KM reconstruction².

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
EORTC 22961, N=970	Locally advanced disease after radiotherapy plus 6 months androgen suppression¹	Continue androgen suppression for 2.5 more years¹	Stop androgen suppression¹	Overall survival¹	Five-year mortality 15.2% with long-course versus 19.0% with short-course suppression; short-course HR for death 1.42¹.	Directly tests duration after radiotherapy, not surgery or abiraterone intensification¹.
STAMPEDE, N=1,974	High-risk nonmetastatic disease on ADT; radiotherapy planned/required by protocol context²	ADT plus abiraterone/prednisolone²	ADT alone²	Metastasis-free survival²	Six-year MFS 82% vs 69%; MFS HR 0.53. OS HR 0.60².	Very-high-risk/cN1 eligibility; not a comparison of local-treatment modalities².

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
Grade Group, PSA, clinical stage, and conventional imaging	Risk and local-therapy selection³⁴	—	Define clinical risk and confirm STAMPEDE-like eligibility before intensification¹²³.	Do not equate a guideline high-risk label with every trial population¹².
Decipher	Not a standard local-therapy selector⁷	NRG-GU009 is testing Decipher-directed ADT duration with radiotherapy⁷	Do not substitute it for trial eligibility outside a protocol⁷.	No efficacy results yet; investigational for ADT-duration tailoring in this setting⁷.
Germline BRCA / HRR	Hereditary-risk counseling and later-line planning³	Broader HRR panels when indicated³	Informs genetic counseling; does not select surgery vs radiotherapy or STAMPEDE abiraterone on this page³.	Not a local-therapy selector in the source pack³.
PSMA PET	Staging information when clinically appropriate³⁵	Expanding use for biochemical recurrence staging³⁵	May refine staging before intensifying systemic therapy or salvage pathways³⁵.	Does not replace conventional staging for applying STAMPEDE-like eligibility as written on this page²³.
MSI / TMB	Later-line immunotherapy consideration only³	Expanding tumor-agnostic use³	Does not select local therapy or ADT intensification in localized high-risk disease³.	Not a local-therapy selector; relevant if metastatic progression leads to later-line options³.

Upcoming research

Field direction: genomic risk–adapted ADT duration and ARPI intensification with radiotherapy are the main care-changing experiments in localized high-risk disease⁷.

Trial	Why it may change care	Evidence status
NRG-GU009 / PREDICT-RT	Tests Decipher-directed ADT duration and apalutamide intensification with radiotherapy in high-risk disease⁷.	Phase 3, active not recruiting; MFS primary endpoint; no efficacy results⁷.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
ADT plus abiraterone/prednisolone versus ADT, STAMPEDE	Grade ≥3 AEs: 37% vs 29%².	Grade ≥3 hypertension 5% vs 1%; grade ≥3/4 ALT elevation 6% vs <1%².	Monitor blood pressure and hepatic tests; promptly report severe headache, chest symptoms, jaundice, or marked fatigue².
Radiotherapy plus androgen suppression, EORTC 22961	The retrieved abstract does not supply a comparable numerical toxicity table¹.	Do not add unverified named-event percentages¹.	Counsel on urinary/bowel change, sexual function, hot flashes, fatigue, bone loss, metabolic and cardiovascular effects¹.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and available rate	Patient action / clinic response
Long-course ADT with definitive radiotherapy	The retrieved EORTC 22961 abstract did not supply a comparable named-event table¹.	Monitor urinary/bowel symptoms during radiotherapy, sexual function, hot flashes, fatigue, bone density, metabolic parameters, and cardiovascular risk; urinary retention, heavy bleeding, or severe bowel symptoms needs prompt contact¹.
ADT plus abiraterone/prednisolone with radiotherapy	STAMPEDE: grade ≥3 hypertension 5% vs 1% and grade ≥3/4 ALT elevation 6% vs <1%².	Check blood pressure, potassium, liver tests, edema, and corticosteroid effects; severe headache, chest symptoms, weakness, jaundice, or edema needs prompt contact².

Epic phrase

#localizedhighriskprostate

Counseling: For radiotherapy plus long-course ADT, EORTC 22961 showed lower 5-year mortality with 3 years vs 6 months of androgen suppression after radiotherapy. In STAMPEDE-like very-high-risk M0 disease, 6-year metastasis-free survival was about 82% vs 69% with ADT alone (MFS HR 0.53 vs ADT alone; OS HR 0.60 vs ADT alone) when abiraterone was added to ADT. These results apply to defined trial populations, not every high-risk localized patient.
Counseling: Reviewed surveillance and de-escalation: after RP, PSA every 3–6 months for 5 years then annually (imaging for symptoms or rising PSA); after RT+ADT, PSA every 6 months with ADT duration per EORTC/STAMPEDE; complete planned ADT (and 2 years abiraterone if STAMPEDE-like); biochemical recurrence after surgery → early salvage RT pathway; metastatic progression → mHSPC page. STAMPEDE published 6-year MFS about 82% vs 69% with ADT alone when abiraterone was added (not a full KM curve).
Counseling: Reviewed sequence: surgery → PSA/pathology-directed surveillance or salvage pathway; or definitive radiotherapy plus long-course ADT, with abiraterone/prednisolone only for the defined STAMPEDE-like very-high-risk/cN1 population. ***
Monitoring: During radiotherapy plus ADT, review urinary/bowel symptoms, sexual function, hot flashes, fatigue, bone, metabolic, and cardiovascular effects. With abiraterone/prednisolone, check blood pressure, potassium, liver tests, and edema. ***
Counseling: Reviewed that STAMPEDE intensification applies to a defined high-risk nonmetastatic population, not every guideline-defined high-risk patient. For abiraterone, reviewed hypertension and liver-test monitoring; promptly report severe headache, chest symptoms, jaundice, or marked fatigue.
Decision: *** selects surgery / radiotherapy plus ADT / radiotherapy plus ADT with abiraterone-prednisolone / clinical-trial evaluation.
Labs/NGS: PSA *, testosterone *, CBC/CMP *; germline testing *; Decipher *** only if it will inform a trial or documented decision.
Procedures: *** radiation-oncology, urologic-oncology, and multidisciplinary review.
Medications: *** ADT and supportive bone/metabolic-health plan.
Follow-up: *** PSA, testosterone, treatment-toxicity, bone-health, and imaging follow-up.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Explicit Setting×PSA×Imaging surveillance table; inserted STAMPEDE 6-year MFS landmark figure; expanded Biomarkers to five-column clinic/emerging format (including PSMA PET and MSI/TMB limits).
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added local-therapy sequencing and all-regimen on-treatment monitoring for ADT, radiotherapy, and abiraterone/prednisolone.
2026-09-21: Created localized high-risk prostate setting page with source-verified ADT-duration and STAMPEDE evidence.

Edit evidence markdown

Evidence page